Inovio Pharma Highlights Early Data From Experimental Drug For Respiratory Tract Disease

  • Inovio Pharmaceuticals Inc INO announced interim results from an ongoing Phase 1/2 trial evaluating INO-3107 for HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults. 
  • RRP is caused primarily by HPV types 6 and/or 11 characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. 
  • In the first cohort of 21 participants, INO-3107 showed a statistically significant improvement in the clinical endpoint of the number of surgical interventions needed to control papilloma growth. 
  • INO-3107 was also observed to be well-tolerated and immunogenic in the trial. 
  • In the trial, treatment with INO-3107 induced cellular responses against both HPV 6 and HPV 11, inducing CD4 and CD8 T cells. All 21 participants demonstrated an increase in peripheral T cells to one or more antigens in INO-3107 post-baseline. 
  • T-cell responses against HPV 6 and HPV 11 were also still observed at Week 52, 43 weeks after treatment with INO-3107, indicating a persistent cellular memory response.
  • INO-3107 was well-tolerated, with all participants completing the trial follow-up. 
  • Results from the second cohort of 11 patients are expected in the first half of 2023.
  • Price Action: INO shares are down 5.21% at $1.55 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!